Table 1.

Treatment summaries.

Pt	Age	Sex	Stage, AJCC 8th ed.	Starting Dabrafenib (D) Dose	Starting Trametinib (T) Dose	Max tolerated dose (D,T) a	Total time (days) on combination therapy	Percentage of time on intended therapy b	Time (days) to first hold	Time (days) to first dose reduction	Reason for discontinuation	Relapse after adjuvant theraphy	Days to Relapse h	Current Status; treatment
1	54	F	IIIC	150 mg BID	2 mg daily	150 mg BID, 2 mg daily	85	23.2%	27	32	pyrexia, chills, elevated liver labs	No	N/A	NED/Obs
2	40	M	IIIC	150 mg BID	2 mg daily	75 mg BID, 2 mg daily	40	11%	3	8	pyrexia, chills, elevated liver labs	unknown	N/A	Lost to follow up
3	40	F	IIIC	150 mg BID	2 mg daily	75 mg BID, 2 mg daily	57	15.6%	13	15	pyrexia, chills, elevated liver labs	No	N/A	Ned/Obs
4	73	F	IIIC	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	67	18.4%	49	N/A	pyrexia, chills, demand ischemia c	Yes -In scar and LN	550	Additional relapse, Systemic treatment
5	62	F	IIIB	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	333	91.2%	49	62	Recurrent URI requiring holds- attributed to tobacco/pulmonary status	Yes -lung	427	Systemic therapy
6	50	F	IIIB	75 mg BID	2 mg daily	150 mg qam 75 mg qpm, 2 mg daily	184	50.4%	18	22	decrease in RV function d	No	N/A	NED/Obs
7	64	M	IIIC	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	38	10.4%	9	N/A	Poor tolerance, patient preference, dilated right atrium e	No	N/A	NED/Obs
8	68	F	IIIB	150 mg BID	2 mg daily	Not reached	19	5.2%	5	10	pyrexia, chills, elevated liver labs, thrombocytopenia, arthralgias	No	N/A	NED/Obs
9	58	M	IIIC	150 mg BID	2 mg daily	150 mg qam 75 mg qhs, 2 mg daily	365	100%	55	67	Completed course	Yes brain	28	DOD
10	46	M	IIIC	75 mg BID	2 mg daily	150 mg qam 75 mg qhs, 2 mg daily	366	100%	29	40	Completed course	Yes -lung and LNs	142	Systemic therapy
11	32	F	IIIA	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	64	17.5%	37	N/A	pyrexia, diarrhea, abdominal pain	Yes -LN	444	NED; s/p systemic therapy and surgery
12	29	M	IIIC	75 mg BID	2 mg daily	150 mg qam 75 mg qhs, 2 mg daily	373	100%	62	N/A	Compled course	No	N/A	NED/Obs
13 f	43	M	IIIC	75 mg BID	2 mg QOD	75 mg BID, 2 mg QOD	50	13.7%	26	49	Pyrexia, chills	No	N/A	NED/Obs
14	21	F	IIIC	75 mg BID	2 mg QOD	75 mg BID, 2 mg QOD	113	31%	25	N/A	Pyrexia, chills	No	N/A	NED/Obs
15	47	M	IIIB	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	32	8.8%	32	N/A	RA and RV dilation dizziness, nausea, fatigue	No	N/A	NED/Obs
16 f	62	M	IIID	75 mg BID	2 mg daily	150 mg BID, 2 mg daily	195	53.4%	N/A	N/A	Disease progression	Disease progression	N/A	s/p Systemic therapy/ CR
17	34	IIIC	M	75 mg BID	2 mg daily	150 mg BID, 2 mg daily	377	100%	N/A	N/A	Completed course; simultaneous relapse	Yes -local	N/A	Systemic treatment for additional relapse
18	38	F	IIIB	150 mg BID	2 mg daily	150 mg BID, 2 mg daily	363	99.4%	94	115	Completed course	No	N/A	NED/Obs
19	40	M	IIIC	75 mg BID	2 mg daily	75 mg BID, 2 mg daily	352 g	96.4%	38	N/A	Pyrexia, chills, elevated liver labs	Yes -brain	1167	Surgery, radiation, systemic therapy
20	40	M	IIIA	75 mg BID	2 mg QOD	75 mg BID, 2 mg QOD	383	100%	60	138	Completed course	No	N/A	NED/Obs

Patients 3,4,7,9,17,18,19, and 20 did not have CLND.

N/A, Not Applicable.

^aMax tolerated dose: Stable on dose for 14 days without adverse events.

^bIntended therapy: one year of combination therapy at any doses; Percentage of time on intended therapy: number of days on combination therapy out of 365 days 100% is maximum.

^cDemand ischemia secondary to pyrexia and chills.

^dRV function normalized on repeat imaging off medication.

^eInitial determination of right atrium dilation was found to be unchanged from baseline after review by a second provider.

BID, twice daily; NED, no evidence of disease; Obs., close observation; D + T, dabrafenib and trametinib; RA, right atria; RV, right ventricle.

^fReceived adjuvant radiation.

^gincludes 45 day hold required for elevated liver enzymes.

^hDays to relapse = time relapse first occurred from day of last dose of adjuvant therapy.